<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419119</url>
  </required_header>
  <id_info>
    <org_study_id>VIDI 2</org_study_id>
    <nct_id>NCT01419119</nct_id>
  </id_info>
  <brief_title>Vitamin Deficiency in Immigrants, a Treatment Study</brief_title>
  <acronym>VIDI2</acronym>
  <official_title>A Study, Four Parallel Arms, Included Two Arms Open Randomisation to Different Doses of Vitamin D, for Assessment of Efficacy of Treatment With Vitamin D at Vitamin D Deficiency, Vitamin D Insufficiency and Suboptimal Levels of Vitamin D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of different doses of vitamin D in
      persons, immigrated to Sweden from Middle East or Africa, with decreased S vitamin D.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants in the study have taken part in a previous screening study. They are now
      asked to participate in this treatment study. At a screening visit blood samples for vitamin
      D3 and PTH are collected. Data regarding previous fractures, life style, exposure for sun,
      clothes, diet, smoking and physical activities are collected. The Vitamin D value predict the
      treatment dose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum-vitamin D</measure>
    <time_frame>12 weeks after treatment start</time_frame>
    <description>Levels of serum vitamin D3 and Serum -parathyroid hormone(PTH) are to be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strengths in hands and legs</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
    <description>Muscle strength in hand is measured with JAMAR dynamometer. Muscle strength in lower legs is measured with Balance test by Ekdahl.
Quality of life questionaries will also be used.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>10 000 IU daily i.e. 15 drops orally once daily for 12 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>Vigantol Oil 20 000 IU/ml, drops for oral use, solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>2000 IU daily i.e. 3 drops orally once a day for 12 weeks,</description>
    <arm_group_label>Group 2a</arm_group_label>
    <other_name>Vigantol Oil 20 000 IU/ml, drops for oral use, solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,</description>
    <arm_group_label>Group 2b</arm_group_label>
    <other_name>Vigantol Oil 20 000 IU/ml, drops for oral use, solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>2000 IU daily i.e. 3 drops orally once daily for 12 weeks</description>
    <arm_group_label>Group 3</arm_group_label>
    <other_name>Vigantol Oil 20 000 IU/ml, drops for oral use, solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum- vitamin D below 75 nmol/L

          -  Men and female

          -  25-65 years of age

          -  Born in Middle East or Africa, living in Umeå district

        Exclusion Criteria:

          -  Hypersensitive to Cholecalciferol, cocos oil, palm kernel or rubber

          -  Serum D3 equal to or above75 nmol/L

          -  Hypercalcemia

          -  Renal insufficiency

          -  History of Kidney Calculi

          -  Nephrocalcinosis

          -  History of sarcoidosis and other Granulomatous Diseases

          -  Known malignancy

          -  Ongoing treatment with phenytoin, barbiturates, rifampicin, isoniazid

          -  Ongoing treatment with cardiac glycosides

          -  Ongoing treatment with thiazides

          -  Ongoing treatment with Etalpha, Rocaltrol, ergocalciferol, Dygratal

          -  Ongoing treatment with drugs involving fat absorption; Orlistat Colestyramin

          -  Oral treatment with glucocorticoids

          -  Ongoing treatment with Aluminum Compounds drugs

          -  Ongoing treatment with Omega -3, vitamin D and/or calcium

          -  Immobilisation

          -  Other medial reason not to participate according to the investigator

          -  Pregnancy (women with S-D3 below 25 nmol/)

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Norberg, M.D. Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Epidemiology and Global Health, Umeå University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ålidhems hälsocentral, Umeå</name>
      <address>
        <city>Umeå</city>
        <zip>Se-90736</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2011</study_first_submitted>
  <study_first_submitted_qc>August 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2011</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Margareta Norberg</investigator_full_name>
    <investigator_title>M.D. Ph.D.</investigator_title>
  </responsible_party>
  <keyword>vitamin D insufficiency</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>D3</keyword>
  <keyword>Parathyroid Hormone</keyword>
  <keyword>25-hydroxyvitamin D3</keyword>
  <keyword>RDA, recommended daily intake (nutrition policy)</keyword>
  <keyword>Vitamin D</keyword>
  <keyword>Hypovitaminosis-D</keyword>
  <keyword>Pharmacologic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

